

# Meet the speakers at the Riyadh Global Medical Biotechnology Summit 2021

“We are now bringing biomedical R&D and stronger clinical trials closer to biotech and biopharma development in the country, in particular in light of the COVID-19 pandemic which has fueled this development at a faster pace.”

—Dr. Bandar Al Knawy  
Chief Executive Officer, Ministry of National Guard Health Affairs President, King Saud bin Abdulaziz University for Health Sciences and Summit President



**Dr. Bandar Al Knawy**  
Chief Executive Officer, Ministry of National Guard Health Affairs President, King Saud bin Abdulaziz University for Health Sciences and Summit President



**Prof. Ahmed Alaskar**  
Executive Director, King Abdullah International Medical Research Center and Summit Chairman



**Dr. Abdelali Haoudi**  
Head R&D Strategy and Business Development, Managing Director, Medical Biotechnology Park and Summit Vice Chairman

## Introduction to Riyadh Global Medical Biotechnology Summit 2021

Prof. Ahmed Alaskar, Executive Director, King Abdullah International Medical Research Center

## Developing a COVID-19 Vaccine for the World at an Unprecedented Pace



Moderated by  
**Mr. Walter Klemp**  
Chairman and CEO Moleculin, Inc.



Keynote Speaker  
**Sir Menelas N. Pangalos**  
Executive Vice President & President BioPharmaceutical R&D, AstraZeneca

## SESSION 1: Biotechnology for the Kingdom of Saudi Arabia: Challenges and Opportunities

Chaired by Prof. Ahmed Alaskar, Executive Director, King Abdullah International Medical Research Center

### Biotechnology in the Kingdom of Saudi Arabia: Challenges and Opportunities - Towards Better Alignment with the Saudi National Vision 2030

Chaired by Prof. Ahmed Alaskar, Executive Director, King Abdullah International Medical Research Center



**Eng. Suliman Almazroua**  
CEO of the National Industrial Development and Logistics Program



**Eng. Nizar Al-Hariri**  
Chief Executive Officer, National Industrial Development Center



**Dr. Ashraf Allam**  
CEO, Pharmaceutical Investment Company



**Dr. Abdulrahman Alnuaim**  
Professor, physician, healthcare executive and pharmaceutical industry consultant at Ministry of Industry



**Dr. Pierre J. Magistretti**  
Director, KAUST Smart Health Initiative



**Dr. Elie Haddad**  
Senior Advisor & Project Lead, Riyadh Biotech City, Royal Commission for Riyadh City



**Dr. Malak Althagafi**  
Director of the General Directorate for the National RDI, King Abdulaziz City for Science and Technology

**“We have learned that it is possible to streamline research that often takes 10 or 20 years into the space of a year.”**

—Prof. Ahmed Alaskar  
Executive Director, King Abdullah International  
Medical Research Center and Summit Chairman

**SESSION 2: Biotechnology Parks/Clusters: Best Practices and Future Trends**

Chaired by Dr. Abdelali Haoudi, Head R&D Strategy and Business Development, Managing Director, Medical Biotechnology Park. Co-chaired by Dr. Klaus Kleinfeld, Senior Advisor to the Ministry of Industry, KSA



**Dr. Klaus Kleinfeld**  
Senior Advisor to  
the Ministry of  
Industry, KSA



**The Munich  
Biotech Cluster:  
Turning Science  
into Innovation**

**Dr. Horst Domdey**  
Chief Executive Officer,  
Biotech Cluster  
Development GmbH



**Medical  
Biotechnology as  
a Strategic Pillar  
for KSA Health  
and Economic  
Development**

**Dr. Mehmood Khan**  
Chief Executive  
Officer, Hevolution  
Foundation



**Driving Biotech  
Success with Agile  
Entrepreneurs**

**Dr. Richard Smith**  
Chief Operating  
Officer, Rockland  
Immunochemicals,  
Inc. USA



**Innovation and  
Intellectual Property  
at KAIMRC/KSAU-HS/  
MNG-HA**

**Dr. Manal Alaamery**  
Head, Developmental  
Medicine, Chairman  
Innovation and  
Entrepreneurship KAIMRC,  
KSAU-HS, MNG-HA



**Structuring  
Incentives  
to Drive  
Biomedical  
Sector Growth**

**Mr. Walter  
Klemp**  
Chairman and  
CEO, Moleculin  
Biotech, Inc.

**SESSION 3: Biotechnology Companies: Global Benchmarking and Partnerships**

Chaired by Dr. Ronald DePinho, MD Anderson Cancer Center



**A Joint Journey into the  
Future: How Biotech  
and Academic Research  
Institutions Can Work  
Together to Foster  
Innovation**

**Dr. Paul Rothman**  
Chief Executive Officer, Johns  
Hopkins University, USA



**Sporos Bioventures:  
A New Model for  
Biotech Creation and  
Development**

**Dr. Ronald DePinho**  
Professor and Past President  
MD Anderson Cancer  
Center, USA



**How Bioentre-  
neurship Works**

**Mr. Brady Huggett**  
Business Editor, *Nature  
Biotechnology*



**The Gene Editing  
Institute at  
ChristianaCare: An  
Innovation Accelerator  
in a Regional  
Healthcare System**

**Dr. Eric Kmiec**  
Founder and Director, The  
Gene Editing Institute,  
Helen F. Graham Cancer  
Center & Research  
Institute, Christiana Care  
Health System



**Open Innovation and  
Entrepreneurship**

**Dr. Hitesh Sangane**  
Executive Director &  
Head of Emerging  
Innovations, AstraZeneca

**Biotechnology Development: Clinical Trials and Manufacturing**

**Keynote Presentation  
Biotechnological advances  
in cardiovascular disease  
management: from a one to a billion**



Moderated by  
**Mr. Markus Peterseim**  
Managing Director, Alvarez &  
Marsal, Frankfurt, Germany



Keynote Speaker  
**Dr. Philip Larsen**  
Senior Vice President & Head  
Global R&D, BAYER AG

## SESSION 4: Medical Biotechnology, Digital Medicine and Clinical Trials

Chaired by Dr. Ali Alessandro Ayach, Alvarez & Marsal



### Biotechnology and Clinical Trials; Adding More Complexity or Facilitating?

**Dr. Majed Al Jeraisy**  
Chairman, Research Office, Director, Clinical Trial Services, KAIMRC



### Real World Evidence in the Era of Digital Health: Opportunities and Challenges

**Dr. Ali Al Qarni**  
Head, KAIMRC- Eastern Region, Deputy Executive Regional Director-Medical Services, MNGHA



### Creating an Ecosystem to Harness Digital and Biotech Innovations for Precision Health

**Dr. Rifat Atun**  
Professor Global Health Systems, Director of Global Health Systems Cluster Harvard University, USA



### Re-imagine Patient Access to Expert Cancer Care in the Era of Digital Medicine

**Dr. Lynda Chin**  
President and Chief Executive Officer, Apricity Health LLC, USA



### Acceleration Clinical Trials in the Digital Era and Commercialization of Outputs

**Dr. Ali Alessandro Ayach**  
Senior Director, Strategy and Performance Improvement Alvarez & Marsal Dubai, UAE

## SESSION 5: Biosimilars and Biotherapeutics Development and Manufacturing

Chaired by Dr. Joshua LaBaer, The Biodesign Institute



### Natural Camelid Single Domain Antibodies as Potential Alternatives to Monoclonal Antibodies in the Next Generation Immunotherapy

**Dr. Hiep Tran**  
President and Chief Scientific Officer, Abzyme Therapeutics LLC



### New Methods for Cell-Free Presentation of Proteins for Functional Analysis

**Dr. Joshua LaBaer**  
Executive Director, The Biodesign Institute



### Developing Cell and Gene Therapies: Challenges and Opportunities

**Dr. Fouad Atouf**  
Vice President, Global Biologics, US Pharmacoepa, USA



### Creating a Biosimilars and Biotherapeutics CDMO Hub

**Mr. Markus Peterseim**  
Managing Director, Alvarez & Marsal, Frankfurt, Germany



**Dr. Waldemar Radziszewski**  
Executive Medical Director, Global Clinical Development, AMGEN

## SESSION 6: Vaccine Development and Manufacturing

Chaired by Dr. Jamila Louahed, GSK



### Biotechnology in Vaccine Development

**Dr. Hani Al Hashmi**  
Senior Medical Affairs Director, Pfizer, KSA



### Innovation in Vaccines

**Dr. Jamila Louahed**  
Vice President and Head, Global R&D, GSK



### Vaccine R&D in KSA: Experience and Challenges

**Dr. Naif Al Harbi**  
Director, Vaccine Development Unit, Director, Research Quality Management Research Scientist, Infectious Diseases Research Department, KAIMRC



### RSV Prevention for All Infants and Children

**Dr. Jon Heinrichs**  
Associate Vice President and Franchise Head, Sanofi Pasteur



### Cytiva and Vaccine Bioprocessing

**Mr. Sven Frie**  
General Manager, Commercial Enterprise Solutions, Cytiva

## Biotechnology Development: Diagnostics and Therapeutics

### Keynote Presentation Messenger RNA: a flexible platform for different therapeutic areas



Moderated by  
**Dr. Manal Alaamery**  
Head, Developmental Medicine, Chairman Innovation and Entrepreneurship KAIMRC, KSAU-HS, MNG-HA



Keynote Speaker  
**Dr. Paolo Martini**  
Senior Vice President, Moderna

## SESSION 7: MedTech/Medical Devices and Diagnostics

Chaired by Mrs. Bouchra Bensaoud, Danaher. Co-Chaired by Mr. Raymond Berglund, Alvarez & Marsal



**Mrs. Bouchra Bensaoud, Danaher**

**Molecular Diagnostics' Role in the Fight Against COVID and Beyond**



**Mr. Iain Sharp-Paul**  
Vice President EMEA Marketing, Cepheid



**Mr. Sherif Harydi**  
General Manager, Middle East, Cepheid



**Oncology Care Pathway: Devices and Tracers**

**Mr. Perry Frederick**  
Senior Director, Strategic Research, Europe, Middle East, and Africa  
GE Healthcare



**MNGHA's Response to Support Ventilator Manufacturing Initiatives by Local SMEs**

**Dr. Ahmed AlZahrani**  
Director of Healthcare Technology Development, Information Technology Department, MNGHA



**Data and the Future of Healthcare in the COVID-19 Era**

**Mr. Elie Chaillot**  
Vice-President and Chief Executive Officer, GE Healthcare, EMEA



**What to Consider in Localization for Manufacturing Medtech/Med Devices**

**Mr. Raymond Berglund**  
Managing Director & Head, Healthcare and Life Science, Alvarez & Marsal

## SESSION 8: Stem Cell Biotechnology and Cellular and Gene Therapy

Chaired by Dr. Miriam Fuchs, Novartis



**Chimeric Antigen Receptor T Cells: Lessons from B Cell Malignancies**

**Dr. Badr Al Ahmari**  
Director, Hematology Fellowship Program, Consultant, Adult Stem Cell Transplant and Cellular Therapy Department of Oncology, KAMC, MNGHA – Riyadh



**Genetically Enhanced T Cells: Designing, Engineering, and Building Cancer Immunotherapies**

**Dr. Joseph Fraietta**  
Director of the Solid Tumor Immunotherapy Laboratory University of Pennsylvania (Philadelphia, PA)



**Saudi Bank of Induced Pluripotent Stem Cells**

**Dr. Khaled Al Sayegh**  
Associate Director, Biomedical Research  
KAIMRC



**Development of the Bacteria Viruses, Bacteriophage, into a Delivery Technology for Therapeutic Genes and DNA Vaccines Against Cancer and Other Human Diseases**

**Dr. Amin Hajitou**  
Professor and Chair, Targeted Therapeutics, Imperial College London, UK



**The Tisagenlecleucel (CAR-T) Experience**

**Dr. Miriam Fuchs**  
Global Therapeutic Area Lead, Cell and Gene Therapies, Oncology, Regulatory Affairs, Novartis

## SESSION 9: Genomics, Genetics, Gene Editing and Bioinformatics

Chaired by Dr. Paolo Martini, Moderna. Co-Chaired by Prof. Majid Alfadhel, King Abdullah International Medical Research Center



**Genetic and Rare Disease Program (GARD): An Opportunity for Orphan Diseases Biotechnology**

**Prof. Majid Alfadhel**  
Deputy Executive Director, KAIMRC, Chairman, Genetics and Precision Medicine Department, King Abdulaziz Medical City



**mRNA Therapy for Propionic Acidemia: From Bench to Bedside**

**Dr. Paolo Martini**  
Senior Vice President, Moderna



**Magnetically Guided Rosette Nanotubes-siRNA Delivery for Cancer Gene Silencing**

**Dr. Hicham Fenniri**  
Professor, Departments of Chemical Engineering, Bioengineering, Chemistry & Chemical Biology, Northeastern University, USA & Chief Scientific Officer, MAScIR Foundation, Morocco



**Beyond Exome: Whole Genome Sequencing for Rare Disease Diagnostics**

**Dr. Madhuri Hegde**  
Vice President and Chief Scientific Officer, PerkinElmer, Inc.



**Empowering Infectious Disease Surveillance Using Whole-genome Sequencing**

**Prof. Majed Al Ghoribi**  
Chairman, Infectious Diseases Research Department, Associate Research Scientist, King Abdullah International Medical Research Center

**nature**research  
custom media

# The 12<sup>th</sup> Annual Forum for Medical Research

RIYADH GLOBAL MEDICAL  
BIOTECHNOLOGY SUMMIT 2021